Transcription and Translation Inhibitors in Cancer Treatment

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Development

Background:

• Transcription and translation are crucial for cellular protein production and are often upregulated in cancer cells to support their growth.
• This upregulation makes cancer cells particularly susceptible to inhibitors of these fundamental processes.
• Numerous protein targets exist within transcription and translation pathways, offering opportunities for cancer drug development.

Purpose of the Study:

• To review the properties and functions of transcription and translation inhibitors tested and developed for cancer treatment.
• To focus on advancements in the field over the last five years.
• To discuss novel strategies targeting transcription factors, oncogenes like KRAS, and RNA molecules.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of natural compounds, synthetic molecules, and nucleic acid-based therapeutic approaches.
• Focus on recent developments in targeting oncogenes and transcription factors.

Main Results:

• Identification of numerous druggable proteins involved in transcription and translation.
• Emerging strategies targeting previously 'undruggable' targets like transcription factors and RNA molecules.
• Advances in DNA and RNA-based therapeutic approaches for cancer treatment.

Conclusions:

• Transcription and translation inhibitors represent a promising class of anti-cancer therapeutics.
• Targeting oncogenes, transcription factors, and RNA offers new avenues for drug development.
• Future research will likely focus on refining these approaches and exploring combination therapies.